Hansa Biopharma AB (OSTO:HNSA) Moat Score: 0/10 (As of Jul. 08, 2026)


OSTO:HNSA Hansa Biopharma AB OSTO:HNSA
49 GF Score
Price kr34.56
GF Value kr24.49
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Hansa Biopharma AB Moat Score?

Hansa Biopharma AB has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Hansa Biopharma AB has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Hansa Biopharma AB might have No Moat - No discernible moat.

Hansa Biopharma AB  (OSTO:HNSA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Hansa Biopharma AB Moat Score Related Terms

OSTO:HNSA
49GF Score
Hansa Biopharma AB OSTO:HNSA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Hansa Biopharma AB (OSTO:HNSA) Overvalued in 2026?

Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued. The current stock price of kr34.56 is trading 41.1% above its estimated GF Value™ of kr24.49. GuruFocus considers Hansa Biopharma AB to be Significantly Overvalued.

Key valuation signals for OSTO:HNSA:

  • Moat Score: 0
  • GF Value™: kr24.49 vs. price of kr34.56 (41.1% above fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the OSTO:HNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hansa Biopharma AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
49GF Score

Get the complete analysis for OSTO:HNSA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr34.56
Price
kr24.49
GF Value